WO1994010317A3 - Vaccin conjugue contre des streptocoques du groupe b - Google Patents

Vaccin conjugue contre des streptocoques du groupe b Download PDF

Info

Publication number
WO1994010317A3
WO1994010317A3 PCT/US1993/010506 US9310506W WO9410317A3 WO 1994010317 A3 WO1994010317 A3 WO 1994010317A3 US 9310506 W US9310506 W US 9310506W WO 9410317 A3 WO9410317 A3 WO 9410317A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptococcus
group
contain
polysaccharide
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/010506
Other languages
English (en)
Other versions
WO1994010317A2 (fr
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
General Hospital Corp
Original Assignee
Brigham and Womens Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, General Hospital Corp filed Critical Brigham and Womens Hospital Inc
Priority to PL93308555A priority Critical patent/PL177302B1/pl
Priority to EP94902202A priority patent/EP0669985A1/fr
Priority to JP6511389A priority patent/JPH08505282A/ja
Priority to FI951979A priority patent/FI951979L/fi
Priority to AU56654/94A priority patent/AU689452B2/en
Priority to HU9501260A priority patent/HU220198B/hu
Publication of WO1994010317A2 publication Critical patent/WO1994010317A2/fr
Publication of WO1994010317A3 publication Critical patent/WO1994010317A3/fr
Priority to NO951629A priority patent/NO951629L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On décrit un vaccin qui protège des infections dues à des streptocoques du groupe B. Ce vaccin présente des fractions polysaccharides-protéines et contient: a) un polysaccharide de streptocoque du groupe B conjugué à b) un dérivé fonctionnel d'un antigène alpha de protéine C d'un streptocoque du groupe B qui garde la capacité d'induire des anticorps protecteurs contre des streptocoques du groupe B. Ce vaccin peut ne contenir qu'un type d'une telle unité polysaccharide-protéine ou un mélange de plusieurs types de ces unités.
PCT/US1993/010506 1992-11-02 1993-11-02 Vaccin conjugue contre des streptocoques du groupe b Ceased WO1994010317A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL93308555A PL177302B1 (pl) 1992-11-02 1993-11-02 Szczepionka sprzężona zdolna do nadania gospodarzowi odporności na infekcje Streptococcus grupy B, cząsteczka rekombinanta, wektor rekombinanta i komórka gospodarza
EP94902202A EP0669985A1 (fr) 1992-11-02 1993-11-02 Vaccin conjugue contre des streptocoques du groupe b
JP6511389A JPH08505282A (ja) 1992-11-02 1993-11-02 Ｂ群連鎖球菌に対する複合ワクチン
FI951979A FI951979L (fi) 1992-11-02 1993-11-02 Ryhmän B Streptococcusten vastaiset konjugaattirokotteet
AU56654/94A AU689452B2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group B streptococcus
HU9501260A HU220198B (hu) 1992-11-02 1993-11-02 Konjugált vakcina B csoportba tartozó Streptococcus ellen
NO951629A NO951629L (no) 1992-11-02 1995-04-28 Konjugat vaksine mot gruppe B streptococcus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
US07/968,866 1992-11-02

Publications (2)

Publication Number Publication Date
WO1994010317A2 WO1994010317A2 (fr) 1994-05-11
WO1994010317A3 true WO1994010317A3 (fr) 1994-07-07

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/010506 Ceased WO1994010317A2 (fr) 1992-11-02 1993-11-02 Vaccin conjugue contre des streptocoques du groupe b

Country Status (14)

Country Link
EP (1) EP0669985A1 (fr)
JP (1) JPH08505282A (fr)
KR (1) KR100349331B1 (fr)
AU (1) AU689452B2 (fr)
CA (1) CA2146926A1 (fr)
FI (1) FI951979L (fr)
HU (1) HU220198B (fr)
IL (1) IL107458A0 (fr)
NO (1) NO951629L (fr)
NZ (1) NZ258684A (fr)
PL (1) PL177302B1 (fr)
RU (1) RU2209247C2 (fr)
WO (1) WO1994010317A2 (fr)
ZA (1) ZA938171B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
WO2000006736A2 (fr) * 1998-07-27 2000-02-10 Microbial Technics Limited Acides nucleiques et proteines de streptococcus groupe b
PT1140994E (pt) * 1998-12-22 2005-11-30 Microscience Ltd Proteinas da superficie externa, suas genes e sua utilizacao
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
EP1325133B1 (fr) 2000-10-13 2012-02-29 ID Biomedical Corporation Antigenes bvh-a2 et bvh-a3 du streptocoque du groupe b
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
RU2487890C2 (ru) 2007-04-16 2013-07-20 МинерваКС Апс Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
RU2387715C2 (ru) * 2008-06-18 2010-04-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЕ ДНК, ОБЕСПЕЧИВАЮЩИЕ ПОЛУЧЕНИЕ ПОЛИПЕПТИДОВ Р6, Р7, Р8, ОБЛАДАЮЩИХ ПРОТЕКТИВНЫМИ СВОЙСТВАМИ В ОТНОШЕНИИ STREPTOCOCCUS AGALACTIAE И СЕЛЕКТИВНО-СВЯЗЫВАЮЩИХ IgA
DK2329020T3 (da) 2008-08-28 2013-06-10 Novartis Ag Celleoverfladepræsentation af polypeptidisoformer ved hjælp af stopcodon-overspringelse
EP3365003A1 (fr) 2015-10-21 2018-08-29 Minervax APS Protéine de fusion immunogène
CA3004631A1 (fr) 2015-12-30 2017-07-06 Minervax Aps Complexe immunogene provoquant une immunite protectrice contre un streptocoque du groupe b
CA3066020A1 (fr) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Methode de traitement
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4066854A1 (fr) 2021-03-29 2022-10-05 MinervaX Protéine de fusion immunogène

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006267A1 (fr) * 1986-04-16 1987-10-22 The Brigham And Women's Hospital, Inc. Antigenes, anticorps, vaccins bacteriens et leur procede de production
WO1991004049A1 (fr) * 1989-09-15 1991-04-04 The General Hospital Corporation Vaccin conjugue pour streptocoque du groube b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006267A1 (fr) * 1986-04-16 1987-10-22 The Brigham And Women's Hospital, Inc. Antigenes, anticorps, vaccins bacteriens et leur procede de production
WO1991004049A1 (fr) * 1989-09-15 1991-04-04 The General Hospital Corporation Vaccin conjugue pour streptocoque du groube b

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Abstracts of the 92nd General Meeting of the American Society for Microbiology 1992 page 69 J. MICHEL ET AL. *
J. MICHEL ET AL.: "Cloned alpha and beta C protein antigens of group B Streptococci elicit protective immunity", INF. IMMUN., vol. 59, no. 6, 1991, pages 2023 - 2028 *
J. MICHEL ET AL.: "Large identical tandem repeating units in the C protein alpha antigen gene bca of group B streptococci", PROC. NATL ACAD. SCI. USA, vol. 89, 1992, pages 10060 - 10064 *
L. BEVANGER ET AL.: "Characterisation of the alpha antigen of the C proteins of group B streptocci using a murine monoclonal antibody", APMIS, vol. 100, 1992, pages 57 - 62 *
M. VALTONEN ET AL.: "Isolation of a C (Ibc) protein from group B Streptococcus which elicits mouse protective antibody", MICROBIAL PATHOGENESIS, vol. 1, no. 2, 1986, pages 191 - 204 *

Also Published As

Publication number Publication date
PL177302B1 (pl) 1999-10-29
NZ258684A (en) 1997-04-24
FI951979A0 (fi) 1995-04-26
IL107458A0 (en) 1994-02-27
NO951629D0 (no) 1995-04-28
ZA938171B (en) 1995-03-07
HU220198B (hu) 2001-11-28
FI951979A7 (fi) 1995-06-29
JPH08505282A (ja) 1996-06-11
CA2146926A1 (fr) 1994-05-11
FI951979L (fi) 1995-06-29
KR100349331B1 (ko) 2003-01-06
NO951629L (no) 1995-07-03
PL308555A1 (en) 1995-08-21
RU2209247C2 (ru) 2003-07-27
EP0669985A1 (fr) 1995-09-06
HUT70981A (en) 1995-11-28
AU689452B2 (en) 1998-04-02
KR950704492A (ko) 1995-11-20
WO1994010317A2 (fr) 1994-05-11
AU5665494A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
WO1994010317A3 (fr) Vaccin conjugue contre des streptocoques du groupe b
EP0866133A3 (fr) Un vaccin de la groupe B de Streptococcus
CA2217178A1 (fr) Vaccins contenant une saponine ainsi qu'un sterol
EP0911036A3 (fr) Structure immunogene à double vecteur
OA09776A (en) "Improved vaccine compositions".
EP1170016A3 (fr) Vaccin à base d' uréase contre une infection hélicobactérienne
GB2322801B (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
NL194940B (nl) Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.
KR930701456A (ko) 세팔로스포린 및 동족체, 제조 및 제약학적 조성물
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
EP0640097A4 (fr) Compositions et procedes de vaccination contre les coronavirus.
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
CA2145397A1 (fr) Vaccins conjugues polysaccharides-proteines contre des streptocoques du groupe b de types ii et v
IL95578A0 (en) Vaccine formed from a poly-saccharide and a protein
EP0837692A4 (fr)
CA2086097A1 (fr) Adjuvants et vaccins
EP1666057A3 (fr) Vaccin acellulaire contenant des antigènes de Bordetella pertussis
NZ239281A (en) Antigenic hiv conjugate, vaccine and pharmaceutical composition
GR3018529T3 (en) Nematode vaccine.
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
AU3991899A (en) Verotoxin b subunit for immunization
EP0385909A3 (fr) Kit ou composition pour la prévention ou le traitement des infections par HIV-1
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI HU JP KR NO NZ PL RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI HU JP KR NO NZ PL RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994902202

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2146926

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 258684

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 951979

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1994902202

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994902202

Country of ref document: EP